Author:
Xu Dongmei,Liu Hongmei,Xiang Meiyi,Feng Alei,Tian Mei,Li Donghua,Mao Yantao,Zhang Li,Zhang Shuisheng,Tian Yuan
Funder
Medicine and Health Technology Development Plan of Shandong Province
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference53 articles.
1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012
2. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study;Chen;Tumori,2012
3. Programmed death ligand-1 expression in non-small cell lung cancer;Velcheti;Lab Invest,2014
4. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
5. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates;Wang;Cancer Immunol Res,2014
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献